Clinical trials
Non-small Cell Carcinoma clinical trials
Below are recruiting non-small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 517 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06604689Recruiting
AI-guided brain radiation for EGFR-mutant lung cancer with brain mets
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07647094RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced squamous lung cancer
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Quzhou, ZhejiangAges 18–75 - NCT06269211RecruitingPhase 2
Immunotherapy before surgery for EGFR-mutated lung cancer
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
Guangzhou, GuangdongAges 18 years+ - NCT04973293Recruiting
Pre-surgery immunotherapy plus chemo and blood-vessel medicine for lung cancer
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05979818RecruitingPhase 1
Propranolol plus immunotherapy and chemo for advanced lung cancer
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
Changsha, HunanAges 18–75 - NCT07630168RecruitingPhase 2
Does infusion timing affect treatment response in solid tumors?
This trial tests whether the time of day you receive your infusion (morning vs. afternoon) affects how well your cancer treatment works. It is for people with advanced lung cancer or head and neck cancer that can be surgically removed.
Chapel Hill, North CarolinaAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT07633626Recruiting
Vortioxetine for thinking problems from ALK lung cancer treatment
This trial tests whether a medication called vortioxetine can help improve memory, focus, and thinking problems caused by lorlatinib, a drug used to treat ALK-positive lung cancer. You would take vortioxetine alongside your current cancer treatment to see if it helps your brain function.
BogotáAges 18 years+ - NCT06632262RecruitingPhase 2
Testing new drugs for cancers with FGFR gene changes
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Guiyang, GuizhouAges 18 years+ - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT07619339RecruitingPhase 1
Study of tepotinib and ivonescimab for non-small cell lung cancer
This trial tests a combination of two drugs, tepotinib and ivonescimab, for people with a certain type of advanced non-small cell lung cancer that has a change called MET exon 14 skipping. The treatment aims to shrink tumors or slow their growth.
Basking Ridge, New JerseyAges 18 years+ - NCT07619599RecruitingPhase 1
PET Scan to Track Lung Cancer Treatment Response
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
Duarte, CaliforniaAges 18 years+ - NCT07613723RecruitingPhase 1
Testing ZI-MA4-1 immunotherapy for advanced solid cancers
This early-stage trial tests a new type of immunotherapy called ZI-MA4-1 in patients with advanced cancers (ovarian, lung, synovial sarcoma, or head and neck) that have stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells that have a specific protein called MAGE-A4.
LondonAges 18–75 - NCT07613424Recruiting
Gene Testing Study for Advanced Lung Cancer
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
BeijingAges 18 years+ - NCT06706713RecruitingPhase 2
Testing BEBT-109 for advanced EGFR exon 20 lung cancer
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT07609121RecruitingPhase 2
Radiation, Chemotherapy, and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07586202RecruitingPhase 2
Testing New Drug Combinations Before Lung Cancer Surgery
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT07584239Recruiting
Physical therapy and relaxation before lung cancer surgery
This trial tests whether physical therapy exercises and relaxation techniques done before surgery can help adults with lung cancer feel stronger, recover better, and have better surgical outcomes. You'll work with specialists to prepare your body and mind for the operation.
Columbus, OhioAges 18 years+ - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06668103RecruitingPhase 2
Study of ABSK043 and Firmonertinib for EGFR-mutant lung cancer
This study tests a new combination of two targeted therapies (ABSK043 and firmonertinib) for people with a specific type of advanced lung cancer. It is for patients whose tumors have an EGFR mutation and are PD-L1 positive.
Hefei, AnhuiAges 18 years+ - NCT07562581RecruitingPhase 2
Two Drugs for Advanced Lung Cancer With KRAS Mutation
This trial tests two drugs (luvometinib and anlotinib) together to treat advanced lung cancer that has a KRAS mutation and has grown despite previous treatment. The goal is to see if this combination helps patients live longer and slows cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+
Hear when a new Non-small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-small cell carcinoma?
- Yes. Clin2 currently lists 517 recruiting non-small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.